latest News

OxStem Appoints Chief Scientific Officer

OxStem Limited is pleased to announce the appointment of Dr. Georg C. Terstappen to the role of Chief Scientific Officer (CSO). Press release here.

Prof Paul Riley Publishes Lymphangiogenesis Paper in Journal of Clinical Investigation

Prof Paul Riley, co-founder of OxStem Cardio, this month published work in the Journal of Clinical Investigation entitled "The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction". Prof Riley's findings support targeting of the lymphatic/immune cell axis as a therapeutic paradigm to promote immune modulation and heart repair.

Dame Kay Davies Honoured by the Royal Society

Dame Kay Davies, co-founder of OxStem, is amongst 24 leading scientists who have been honoured by the Royal Society today, in recognition of her outstanding contribution to science. She joins some of the world's most famous scientists to receive a Royal Society award including Albert Einstein, Charles Darwin, Francis Crick, Dorothy Hodgkin, and Stephen Hawking. Full details here.

OxStem Limited Strengthens Management Team

OxStem are delighted to announce the appointment of Dr Carolyn Porter as Chief Business Officer and Dr Andy Mulvaney as Chief Operating Officer. Press release here.

OxStem Featured in Nature

OxStem are delighted to be featured in the May 2017 issue of Nature in an article entitled “Masters of Medicine”. OxStem was selected as one of six innovative and disruptive University start-up biotechnology companies from around the world to be profiled in the article.

More News

Oncology

OxStem Oncology aims to develop unique treatments for a wide range of cancer types. While current therapies can remove the majority of the tumour, the ‘cancer stem-like cells’ (CSLCs) that account for a very small proportion of the tumour can persist unaffected by numerous therapeutic interventions. OxStem Oncology aims to identify a new class of drugs that will differentiate CSLCs to more benign states and improve clinical outcomes and overcome resistance/relapse. 

NEURO

OxStem Neuro will identify a new class of drugs that will stimulate de novo neuron production from neural stem cells that will compensate for disease pathology in neurodegenerative diseases, such as Alzheimer’s disease, and restore cognitive function. OxStem Neuro’s approach aims to significantly reduce the impact of the disease on cognitive function, by replenishing the lost neurons.

Ocular

OxStem Ocular aims to devise treatments for degenerate retinopathies by identifying a new class of drugs that will stimulate appropriate precursor cells within the retina of patients and increase the photoreceptor numbers to restore vision. The identification of small molecules able to repair damaged cells in vivo would represent a step change, overcoming many of the limitations of current therapies.